With fresh capital and a new pipeline strategy, Replicor aims to tackle chronic viral infections and rare liver …
With fresh capital and a new pipeline strategy, Replicor aims to tackle chronic viral infections and rare liver …
ExoGene’s novel delivery platform earns RMAT status for its lead candidate EXG-401, targeting neuroinflammation and motor neuron survival …
Personalized mRNA cancer vaccine combined with Keytruda delivers sustained recurrence-free survival in high-risk melanoma patients, reinforcing immunotherapy’s future.
Already a subscriber? Log in